Back to search
FDAFDA · Food and drugs·Recall number D-0448-2026

GE Healthcare Omnipaque (iohexol) Injection, 350 mg/mL (64.7%), Rx Only, Distributed by: GE Healthcare Inc., Marlborough, MA 01752 USA, NDC 0407-1414-91.

Published April 15, 2026 · Recall initiated: March 24, 2026

Summary

FDA records drug Class II recall D-0448-2026, published April 15, 2026 and initiated March 24, 2026. Recalling firm: GE Healthcare Ireland Limited; Status: Ongoing; Reported quantity: 306,810 vials; Lot: Lot# 17333197; Exp. December 10, 2028 Lot# 17333198; Exp. November 17, 2028 Lot# 17396945; Exp. December 18, 2028 Lot# 17396948; Exp. December 22, 2028 Lot# 17396953; Exp. January 11, 2029 Lot# 17396956; Exp. January 9, 2029 Lot# 17423503; Exp. January 1, 2029 Lot# 17423525; Exp. January 3, 2029 Lot# 17426429; Exp. January 1, 2029 Lot# 17426440; Exp. January 4, 2029 Lot# 17431310; Exp. January 11, 2029. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Presence of particulate matter

What to do

Voluntary: Firm initiated

Get an email if OMNIPAQUE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
OMNIPAQUE
Manufacturer
GE Healthcare Ireland Limited
Distributor
U.S. Nationwide.
Lot
Lot# 17333197; Exp. December 10, 2028 Lot# 17333198; Exp. November 17, 2028 Lot# 17396945; Exp. December 18, 2028 Lot# 17396948; Exp. December 22, 2028 Lot# 17396953; Exp. January 11, 2029 Lot# 17396956; Exp. January 9, 2029 Lot# 17423503; Exp. January 1, 2029 Lot# 17423525; Exp. January 3, 2029 Lot# 17426429; Exp. January 1, 2029 Lot# 17426440; Exp. January 4, 2029 Lot# 17431310; Exp. January 11, 2029
Risk classification
Class II
Area (FDA)
drug
Country
Ireland

Related recalls

Questions about this recall

Was GE Healthcare Omnipaque (iohexol) Injection, 350 mg/mL (64.7%), Rx Only, Distributed by: GE Healthcare Inc., Marlborough, MA 01752 USA, NDC 0407-1414-91. recalled?

Yes. FDA published recall D-0448-2026 on April 15, 2026. Reported hazard: Presence of particulate matter

What should I do if I have this product?

Voluntary: Firm initiated

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: OMNIPAQUE.